赛升药业实控人方拟套现约1.2亿 去年亏损前年扣非亏

Group 1 - The core point of the news is that Sai Sheng Pharmaceutical (300485.SZ) announced a share reduction plan by its controlling shareholders and actual controllers, which will not affect the company's control or governance structure [1] - The shareholders, Ma Li and Liu Shuqin, plan to reduce their holdings by up to 9,633,328 shares, representing 2% of the total share capital of 481,666,400 shares, within a three-month period starting from October 21, 2025 [1] - The estimated cash amount from the share reduction is approximately 116 million yuan, based on the closing price of 12.08 yuan on September 19, 2025 [1] Group 2 - In 2024, Sai Sheng Pharmaceutical reported operating revenue of 416.48 million yuan, a decrease of 12.61% compared to 2023 [2][3] - The net profit attributable to shareholders was -68.85 million yuan, a decline of 166.90% from the previous year, where it was 102.92 million yuan [2][3] - The net profit after deducting non-recurring gains and losses was 11.76 million yuan, showing a significant improvement of 127.94% compared to the previous year's loss of 42.09 million yuan [2][3] - The net cash flow from operating activities reached 135.97 million yuan, an increase of 541.05% year-on-year [2][3]